Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-12 of 12 for your search:
Cancer Type/Condition:
Anal cancer
Stage/Subtype:
stage IV anal cancer
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of Erlotinib Hydrochloride and Cetuximab in Patients With Advanced Gastrointestinal, Head and Neck, Non-Small Cell Lung, or Colorectal Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
VU-VICC-GI-0622
, VICC-GI-0622, 6980, NCI-6980, NCT00397384
2.
Evaluation of Single Session Stereotactic Body Radiotherapy
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2005-0445
, NCT00492817
3.
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
ID02-446
, NCT00508443
4.
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ITL-002-CRYO
, NCT00861107
5.
Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
GRID
, NCT00765570
6.
Phase I Study of UCN-01 and Irinotecan in Patients With Resistant Solid Tumors or Locally Recurrent or Metastatic Triple-Negative Breast Cancer (Part I Closed to Accrual as of 6/8/2007)
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UVACC-SCC-0102
, WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
7.
Gene Therapy for Pleural Malignancies
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
803776
, UPCC 03505, NCT00299962
8.
Phase I Study of Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium in Patients With Advanced Gastrointestinal Cancer
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC064G
, MC064G, NCT00654160
9.
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Phase:
No phase specified
Type:
Natural history/Epidemiology, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2003-0529
, NCT00394602
10.
Pilot Study of MDR modulator CBT-1 and Paclitaxel in Patients With Refractory, Recurrent, or Advanced Metastatic Solid Tumors
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0035
, 08-C-0035, NCT00658424
11.
QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
Phase:
No phase specified
Type:
Natural history/Epidemiology, Treatment
Status:
Active
Age:
30 to 70
Sponsor:
Other
Protocol IDs:
SU-11062007-812
, 96405, ANAL0002, NCT00568425, NCT00568425
12.
Comparison of Standard of Care or Treatment on Protocol
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
INST 0813
, NCT01010334
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
